
Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds
Episode 398
J&J will pay $2.2 billion upfront to acquire Ollin, a Texas-based NewCo with China-sourced assets, gaining a late-stage VEGF x Ang2 bispecific for wet AMD and diabetic macular edema. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the terms of the deal, what it says about NewCos as an exit path and Blackstone Life Sciences’ role in funding Phase III. The analysts also assess how a growing neoantigen vaccine pipeline is testing the modality’s reach after Merck and Moderna’s Phase III win in melanoma, and the White House push that has put Heidi Overton back in play ahead of the Nov. 18 Senate HELP Committee vote on her nomination as FDA commissioner. This episode of the BioCentury This Week podcast has been brought to you by Tigermed. View full story: https://www.biocentury.com/article/661638 #NewCos #BiotechMA #CancerVaccines #FDA #Ophthalmology 0:01 Sponsor Message: Tigermed 1:58 J&J’s Ollin Acquisition 5:18 Blackstone’s Risk Sharing 9:13 Neoantigen Vaccine Pipeline 17:29 Overton’s FDA Nomination 24:40 Acting Commissioner Scenarios To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text
Publisher
BioCentury This Week
Published
November 17, 2026
Duration
29 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
BioCentury
BioCentury This Week
@biocenturythisweek
#neoantigenvaccines #overtonodds #lifesciences
